Immunovant, Inc. Warrants expiring 12/18/2024
IMVTW
IMVTW was delisted on the 15th of June, 2020.
0 hedge funds and large institutions have $0 invested in Immunovant, Inc. Warrants expiring 12/18/2024 in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 17 closing their positions.
100% less funds holding
Funds holding: 17 → 0 (-17)
100% less capital invested
Capital invested by funds: $20M → $0 (-$20M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 17
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$6.88M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.45M |
| 3 |
GL
Governors Lane
New York
|
-$1.99M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.56M |
| 5 |
CAC
Cowen and Company
New York
|
-$1.38M |
IMVTW Hedge Fund Activity: Q2 2020 in Review
0 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Immunovant, Inc. Warrants expiring 12/18/2024 (IMVTW) for Q2 2020, worth a combined $0 — down 100% from $20M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of IMVTW and 0 opened new positions — a net loss of 17 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Boothbay Fund Management, exiting entirely with an estimated $6.88M sold.
- 0 institutional investors held Immunovant, Inc. Warrants expiring 12/18/2024 (IMVTW) as of Q2 2020, down from 17 in Q1 2020.
- Funds reported $0 of Immunovant, Inc. Warrants expiring 12/18/2024 stock for Q2 2020, down 100% quarter-over-quarter.
- 0 funds opened new Immunovant, Inc. Warrants expiring 12/18/2024 positions in Q2 2020 and 17 closed out, a net change of -17 holders.
- The largest Immunovant, Inc. Warrants expiring 12/18/2024 seller in Q2 2020 was Boothbay Fund Management, an estimated $6.88M sold.
Based on aggregated 13F filings for Q2 2020.